Oral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study

Strategies using oral arsenic trioxide (As2O3) are efficacious in relapsed acute promyelocytic leukemia (APL), but they have not been examined in newly diagnosed cases.

[1]  Xiao-jun Huang,et al.  Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[2]  C. Kumana,et al.  Long‐term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide‐based reinduction and maintenance regimens: A 15‐year prospective study , 2018, Cancer.

[3]  E. Estey,et al.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.

[4]  N. Schmitz,et al.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Hills,et al.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[6]  P. Kligfield,et al.  Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[8]  J. Reynolds,et al.  All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). , 2012, Blood.

[9]  S. Lok,et al.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.

[10]  W. Au,et al.  Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients , 2012, Pediatric blood & cancer.

[11]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[12]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[13]  M. Vignetti,et al.  Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. , 2010, Blood.

[14]  M. Tallman,et al.  How I treat acute promyelocytic leukemia. , 2009, Blood.

[15]  W. Hiddemann,et al.  High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG , 2009, Leukemia.

[16]  H. Dombret,et al.  Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[18]  C. Lau,et al.  Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. , 2006, Blood.

[19]  C. Kumana,et al.  Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. , 2003, Blood.

[20]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[21]  Y. Kwong,et al.  Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies , 2002, European Journal of Clinical Pharmacology.

[22]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[24]  C. Kumana,et al.  Oral arsenic trioxide – based maintenance regimens for first complete remission of acute promyelocytic leukemia : a 10-year follow-up study , 2011 .

[25]  S J Chen,et al.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. , 1999, Blood.